IDIX Related Analyst Ratings
-
Vertex (VRTX) VX-135 Looks Interesting, Thinks Deutsche Bank
-
Baird Starts Idenix Pharmaceuticals Inc. (IDIX) at Neutral; No Great Pipeline but Patents Could Have Value
-
Wedbush Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Neutral
-
Deutsche Bank Starts Idenix Pharmaceuticals Inc. (IDIX) at Buy
-
Maxim Group Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Hold
-
BofA/Merrill Lynch Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Neutral
-
UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)
-
Barclays on U.S. Biopharmaceuticals: Fate of Nucs Under Harsh Scrutiny - More Angst for IDIX; GILD Widens Lead
-
Barclays Lowers Outlook on Idenix Pharmaceuticals (IDIX); Clarity on FDA Clinical Hold (BMY, VRTX, GILD)
-
Leerink Swann maintains an 'Outperform' on Idenix Pharmaceuticals (IDIX); Clinical Hold Feels More Like Precaution
-
Jefferies Maintains a 'Hold' on Gilead Sciences (GILD); We Don't Believe
-
Brean Murray Carret & Co. Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Hold; IDX184 on Clinical Hold Again
-
Stifel Nicolaus Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Hold
-
Deutsche Bank Defends Gilead Sciences (GILD) on Sector Setback
-
UPDATE: UBS Starts Idenix Pharmaceuticals Inc. (IDIX) at Buy: Keys To Success
-
Maxim Group Starts Idenix Pharmaceuticals Inc. (IDIX) at Buy
-
Brean Murray Sees Recent Upside in Idenix (IDIX) Related to Possible Gilead (GILD) Settlement in June
-
JMP Securities Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Market Perform
-
Credit Suisse Assumes Coverage on Idenix Pharmaceuticals Inc. (IDIX) at Neutral
-
Idenix (IDIX) Shares at Intraday Low; INFORM-SVR Data Has Negative Implications & Abbott (ABT) Positive Hep C Studies
-
Wedbush Assumes Coverage on Idenix Pharmaceuticals Inc. (IDIX) at Outperform; Market Potential for IDX184 Makes For Attractive Takeover Candidate
-
Leerink Swann Maintains an 'Outperform' on Idenix Pharmaceuticals (IDIX); Addressing USPTO Interference For GILD/ IDIX Patent Claims
-
Wedbush Raises Price Target on Idenix Pharmaceuticals (IDIX) Following Pipeline Update
-
Brean Murray Carret & Co. Maintains a 'Sell' on Idenix Pharmaceuticals (IDIX); Hep C Pipeline Progresses, But Future Development Strategy Appears Risky
-
Barclays on U.S. Pharma: A New Era for Hep C Therapy - Starts Coverage on GILD & IDIX
-
Barclays Starts Idenix Pharmaceuticals (IDIX) at Equalweight
-
William Blair Lifts Target on Idenix (IDIX) to $14 Following Removal of Clinical Hold
-
Brean Murray Raises Red Flag on Idenix (IDIX) After GS-7977 Data from Gilead
-
Idenix Pharmaceuticals (IDIX) Slammed As Shares Slapped with a "Sell"
-
Stifel Nicolaus Downgrades Idenix Pharmaceuticals (IDIX) to Sell
-
Big Pharma Companies Drooling Over Idenix (IDIX) Following BMY/INHX Deal
-
JMP Cuts Idenix (IDIX) to Market Underperform, Sets $4 Price Target
-
Wall Street Hot and Bothered About Idenix (IDIX) and Achillion (ACHN) After INHX/BMY Deal
-
Brean Murray Carret & Co. Maintains a 'Sell' on Idenix Pharmaceuticals (IDIX); GSK Termination of HIV License is a Non-Event
-
Biotech M&A Will Be In Focus in 2012 - Goldman
-
William Blair Upgrades Idenix Pharmaceuticals (IDIX) to Outperform
-
Wedbush Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Outperform; Expect Growing Visibility for IDX184
-
Wedbush Downgrades Anadys Pharmaceuticals (ANDS) to Neutral; Announces Acquisition by Roche; Additional Takeover Targets Remain
-
Wedbush Starts Idenix Pharmaceuticals Inc. (IDIX) at Neutral; IDX184 Has Blockbuster Potential, But Current Risk/Reward Balanced
-
JPMorgan Starts Idenix Pharmaceuticals Inc. (IDIX) at Overweight
-
Brean Murray Carret & Co. Starts Idenix Pharmaceuticals Inc. (IDIX) at Sell, $3 Price Target
-
BofA/Merrill Lynch Upgrades Idenix Pharmaceuticals Inc. (IDIX) to Buy
-
Morgan Stanley Starts Idenix Pharmaceuticals Inc. (IDIX) at Equalweight
-
ThinkEquity Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Sell
-
Stifel Nicolaus Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Hold
-
Oppenheimer Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Perform
-
BofA/Merrill Lynch Starts Idenix Pharmaceuticals Inc. (IDIX) at Neutral
-
Gleacher & Co Initiates Coverage on Biotechnology/Drug Manufacturers Stocks (IDIX, VRUS, & VRTX)
-
JMP Securities Downgrades Idenix Pharma (IDIX) to Market Perform
-
Stifel Nicolaus Initiates Coverage on Idenix Pharmaceuticals (IDIX) with a Buy
Back to IDIX Stock Lookup
